liver cancer, colorectal cancer
Conditions
Interventions
Abound(TM)
Sponsors
Takasaki General Medical Center, National Hospital Organization
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Liver cancer treated by sorafenib 1)The patients confirmed by histological or abdominal imaging examination. 2)Child-Pugh grade A 3)without severe renal dysfunction 4)A written agreement is provided. 2.Colorectal cancer treated by regorafenib 1)The patients confirmed by histological or abdominal imaging examination. 2)without severe renal dysfunction 3)A written agreement is provided. 3.Colorectal cancer treated by panitumumab 1)The patients confirmed by histological or abdominal imaging examination. 2)without k-ras or all ras mutant 3)without severe renal dysfunction 4)A written agreement is provided.
Exclusion criteria
Exclusion criteria: 1)Child-Pugh grade B or C 2)Age is less than 20 years old. 3)The patients who judged a doctor to be inappropriate as an object of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Protective efficacy of dermatopathy | — |
Countries
Japan
Contacts
Public ContactAtsushi Naganuma
Takasaki General Medical Center, National Hospital Organization Department of Gastroenterology
Outcome results
None listed